Literature DB >> 19722894

Prospects for developing an effective particle-mediated DNA vaccine against influenza.

Eric J Yager1, Hansi J Dean, Deborah Heydenburg Fuller.   

Abstract

Vaccine strategies capable of conferring broad protection against both seasonal and pandemic strains of influenza are urgently needed. DNA vaccines are an attractive choice owing to their capacity to induce robust humoral and cellular immune responses at low doses and because they can be developed and manufactured rapidly to more effectively meet the threat of an influenza epidemic or pandemic. Particle-mediated epidermal delivery (PMED), or the gene gun, is a DNA vaccine delivery technology shown to induce protective levels of antibody and T-cell responses in animals and humans against a wide variety of diseases, including influenza. This review focuses on current advances toward the development of an effective PMED DNA vaccine against influenza, including strategies to enhance vaccine immunogenicity, the potential for PMED-based DNA vaccines to improve protection in the vulnerable elderly population, and the prospects for a vaccine capable of providing cross-protection against both seasonal and pandemic strains of influenza.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19722894     DOI: 10.1586/erv.09.82

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  17 in total

Review 1.  Clinical applications of DNA vaccines: current progress.

Authors:  Bernadette Ferraro; Matthew P Morrow; Natalie A Hutnick; Thomas H Shin; Colleen E Lucke; David B Weiner
Journal:  Clin Infect Dis       Date:  2011-08-01       Impact factor: 9.079

Review 2.  DNA vaccines for targeting bacterial infections.

Authors:  Mariana Ingolotti; Omkar Kawalekar; Devon J Shedlock; Karuppiah Muthumani; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

Review 3.  Novel vaccine approaches for protection against intracellular pathogens.

Authors:  Kristin L Griffiths; Shabaana A Khader
Journal:  Curr Opin Immunol       Date:  2014-03-06       Impact factor: 7.486

4.  Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans.

Authors:  Marie Borggren; Jens Nielsen; Karoline Bragstad; Ingrid Karlsson; Jesper S Krog; James A Williams; Anders Fomsgaard
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Advances in Gene Delivery Systems.

Authors:  Kenya Kamimura; Takeshi Suda; Guisheng Zhang; Dexi Liu
Journal:  Pharmaceut Med       Date:  2011-10-01

6.  DNA vaccination elicits protective immune responses against pandemic and classic swine influenza viruses in pigs.

Authors:  J Patrick Gorres; Kelly M Lager; Wing-Pui Kong; Michael Royals; John-Paul Todd; Amy L Vincent; Chih-Jen Wei; Crystal L Loving; Eraldo L Zanella; Bruce Janke; Marcus E Kehrli; Gary J Nabel; Srinivas S Rao
Journal:  Clin Vaccine Immunol       Date:  2011-09-14

7.  Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch.

Authors:  Yeu-Chun Kim; Jae-Min Song; Aleksandr S Lipatov; Seong-O Choi; Jeong Woo Lee; Ruben O Donis; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz
Journal:  Eur J Pharm Biopharm       Date:  2012-04-03       Impact factor: 5.571

Review 8.  Cutaneous immunization: an evolving paradigm in influenza vaccines.

Authors:  Harvinder S Gill; Sang-Moo Kang; Fu-Shi Quan; Richard W Compans
Journal:  Expert Opin Drug Deliv       Date:  2014-02-12       Impact factor: 6.648

9.  GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates.

Authors:  Peter T Loudon; Eric J Yager; Debbie T Lynch; Amithi Narendran; Cristy Stagnar; Anthony M Franchini; James T Fuller; Phil A White; Julia Nyuandi; Clayton A Wiley; Michael Murphey-Corb; Deborah H Fuller
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

10.  A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.

Authors:  Xinle Cui; Zhouhong Cao; Goutam Sen; Gouri Chattopadhyay; Deborah H Fuller; James T Fuller; Dustin M Snapper; Andrew L Snow; James J Mond; Clifford M Snapper
Journal:  Vaccine       Date:  2013-05-09       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.